Literature DB >> 31206999

NICE guidelines on prostate cancer 2019.

Prokar Dasgupta1, John Davis2, Simon Hughes3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31206999     DOI： 10.1111/bju.14815

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  12 in total

1.  Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.

Authors:  Xiaoting Wei; Jianmin Xu; Shuyuan Zhong; Jinsen Zou; Zhiqiang Cheng; Zhiguang Ding; Xuhui Zhou
Journal:  Abdom Radiol (NY)       Date:  2022-07-05

2.  Effect of Clinical Parameters on Risk of Death from Cancer after Radical Prostatectomy in Men with Localized and Locally Advanced Prostate Cancer.

Authors:  Daimantas Milonas; Tomas Ruzgas; Zilvinas Venclovas; Daniele Jonusaite; Aivaras Jonas Matijosaitis; Darius Trumbeckas; Edmundas Varpiotas; Stasys Auskalnis; Darijus Skaudickas; Ramunas Mickevicius; Kestutis Vaiciunas; Jonas Mickevicius; Mindaugas Jievaltas
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

Review 3.  Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.

Authors:  Gaëtan Devos; Wout Devlies; Gert De Meerleer; Marcella Baldewijns; Thomas Gevaert; Lisa Moris; Daimantas Milonas; Hendrik Van Poppel; Charlien Berghen; Wouter Everaerts; Frank Claessens; Steven Joniau
Journal:  Nat Rev Urol       Date:  2021-09-15       Impact factor: 14.432

4.  The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis.

Authors:  Ahmed Abdelhafez; Khaled Hosny; Ahmed R El-Nahas; Matthew Liew
Journal:  Arab J Urol       Date:  2022-02-27

5.  Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis.

Authors:  Joseph M Norris; Benjamin S Simpson; Marina A Parry; Clare Allen; Rhys Ball; Alex Freeman; Daniel Kelly; Alex Kirkham; Veeru Kasivisvanathan; Hayley C Whitaker; Mark Emberton
Journal:  BMJ Open       Date:  2020-01-27       Impact factor: 2.692

6.  Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.

Authors:  Yuka Kubota; Shingo Hatakeyama; Tohru Yoneyama; Mihoko Sutoh Yoneyama; Itsuto Hamano; Sakae Konishi; Teppei Okamoto; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  World J Urol       Date:  2021-03-06       Impact factor: 4.226

7.  Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study.

Authors:  Joseph M Norris; Lucy A M Simmons; Abi Kanthabalan; Alex Freeman; Neil McCartan; Caroline M Moore; Shonit Punwani; Hayley C Whitaker; Mark Emberton; Hashim U Ahmed
Journal:  Eur Urol Open Sci       Date:  2021-06-15

8.  Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study.

Authors:  Lois Kim; Nicholas Boxall; Anne George; Keith Burling; Pete Acher; Jonathan Aning; Stuart McCracken; Toby Page; Vincent J Gnanapragasam
Journal:  BMC Med       Date:  2020-04-17       Impact factor: 8.775

9.  Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis.

Authors:  Joseph M Norris; Lina M Carmona Echeverria; Benjamin S Simpson; Rhys Ball; Alex Freeman; Daniel Kelly; Alex Kirkham; Hayley C Whitaker; Mark Emberton
Journal:  BMJ Open       Date:  2020-10-22       Impact factor: 2.692

10.  Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients.

Authors:  Luke L Wang; Brandon L Henslee; Peter B Sam; Chad A LaGrange; Shawna L Boyle
Journal:  Prostate Cancer       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.